ReSPECT™ Clinical Trials
  • LEPTOMENINGEAL METASTASES (LM)
    • CANCER GUIDE FOR PATIENTS
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
      • RESOURCES
    • CLINICAL TRIAL
      • TRIAL INFORMATION
      • PATIENT ELIGIBILITY
      • PRINCIPAL INVESTIGATORS
      • TRIAL LOCATIONS
      • CONTACT US
      • NEXT STEPS
      • NEWS
      • PUBLICATIONS
      • RESOURCES
  • RECURRENT GLIOBLASTOMA (GBM)
    • CANCER GUIDE FOR PATIENTS
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
      • RESOURCES
    • CLINCIAL TRIAL
      • TRIAL INFORMATION
        • QUICK OVERVIEW
      • TRIAL GUIDE FOR PATIENTS
      • PATIENT ELIGIBILITY
      • PRINCIPAL INVESTIGATORS
      • TRIAL LOCATIONS
      • NEXT STEPS
      • CONTACT US
      • NEWS
      • PUBLICATIONS
      • RESOURCES
  • PEDIATRIC BRAIN CANCER
    • CANCER GUIDE FOR PATIENTS- EPENDYMOMA
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
    • CANCER GUIDE FOR PATIENTS – HIGH GRADE GLIOMA
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
    • CLINICAL TRIAL
      • TRIAL INFORMATION
      • PRINCIPAL INVESTIGATORS
      • TRIAL LOCATIONS
      • NEXT STEPS
      • NEWS
      • PUBLICATIONS
      • RESOURCES
Select Page

ReSPECT-LM Receives Additional $1.9 Million Advance Payment From CPRIT

by Plus Therapeutics | Sep 22, 2025 | LM

Plus Therapeutics, Inc. (Nasdaq: PSTV) today announced it has received an additional $1.9 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT) — the second-largest public cancer research funder globally. This latest payment is...

Leading Experts Discuss Leptomeningeal Metastases at SNO/ASCO CNS Metastases Conference

by Plus Therapeutics | Sep 4, 2025 | LM

Last month, several of the world’s leading experts in leptomeningeal metastases (LM) came together at the American Society of Clinical Oncology (ASCO) / Society for Neuro-Oncology (SNO) CNS Metastases Conference to share insights, research, and clinical updates on...

Highlighting Leptomeningeal Metastases at SNO/ASCO 2025

by Plus Therapeutics | Aug 20, 2025 | LM

Last week, the leadership teams of Plus Therapeutics and CNSide Diagnostics came together onsite at the SNO/ASCO 2025 CNS Metastases Conference to advance the dialogue on leptomeningeal metastases (LM). LM Symposium The jointly sponsored LM presentation and panel...

Understanding LM in Lung Cancer by Leptomeningeal Cancer Foundation

by Plus Therapeutics | Aug 19, 2025 | LM

The Leptomeningeal Cancer Foundation is hosting an important webinar on Thursday, August 21, 2025 at 11 AM PDT / 2 PM EDT, featuring two leading oncologists: Dr. Seema Nagpal – neuro-oncologist Dr. Mohana Roy – thoracic oncologist Date & Time: Thursday, August 21,...

Positive ReSPECT-LM Phase 1 Data at SNO/ASCO CNS Metastases Conference

by Plus Therapeutics | Aug 18, 2025 | LM

Plus Therapeutics (NASDAQ: PSTV) announced positive data from the ReSPECT-LM Phase 1 single dose escalation clinical trial, presented at the podium during the Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference....

CNSide® CSF Assay Platform at 2025 SNO/ASCO CNS Metastases Conference

by Plus Therapeutics | Aug 14, 2025 | LM

Plus Therapeutics (NASDAQ: PSTV) presented encouraging data from a retrospective analysis of the CNSide® Cerebrospinal Fluid (CSF) Assay Platform at the 2025 Society for Neuro-Oncology (SNO) / American Society of Clinical Oncology (ASCO) CNS Metastases Conference in...
« Older Entries

Recent Posts

  • ReSPECT Team Supports Cancer Research at the Winship 5K During Breast Cancer Awareness Month
  • ReSPECT-LM Receives Additional $1.9 Million Advance Payment From CPRIT
  • September Is Childhood Cancer Awareness Month
  • Targeted Radiotherapies and Brain Tumor Treatment Challenges on The Bio Report Podcast
  • Plus Therapeutics CEO Highlights the Role of Precision Medicine in Cancer Treatment

Recent Comments

    • Expanded Access Policy
    • Privacy Policy
    • Terms of Use
    • Forward Looking Statement
    • Social Media Guidelines
    • ReSPECT Blog
    Copyright © 2025 Plus Therapeutics, Inc. All rights reserved. ReSPECT is a trademark of Plus Therapeutics, Inc. This website is intended for a U.S. audience only.
    This site uses cookies to improve your experience. A cookie is a file sent to your device when you access a site. By using this site, you agree to the use of cookies on your device for tracking and analytics. Cookie SettingsACCEPT
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
    Non-necessary
    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
    SAVE & ACCEPT